The study aimed to describe the clinical journey of patients with advanced or metastatic NSCLC in second- and third-line treatment settings. Researchers focused on key outcomes, including time to ...

Ellipses has agreed to in-license global rights to ‘GENA-104’, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, a recently discovered checkpoint protein that is highly ...

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Read More on BOLT: ...

PENNINGTON, N.J., June 3, 2025 /PRNewswire/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US ...

CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...

Lugano, Switzerland, 2 December 2024 – The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts ...